The theme of World Kidney Day 2024 is “kidney health for all — advancing equitable access to care and optimal medication practice”. To mark this event, Nature Reviews Nephrology invited five researchers from different geographical regions worldwide to discuss the impact of new and emerging therapies for diabetic kidney disease on patient care as well as the barriers that must be overcome to ensure equitable access to these therapies.
This is a preview of subscription content, access via your institution
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on SpringerLink
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Gheith, O. et al. Diabetic kidney disease: worldwide difference of prevalence and risk factors. J. Nephropharmacol 5, 49–56 (2016).
Shah, V. N. & Mohan, V. Diabetes in India: what is different? Curr. Opin. Endocrinol. Diabetes Obes. 22, 283–289 (2015).
Barbour, S. J., Er, L., Djurdjev, O., Karim, M. & Levin, A. Differences in progression of CKD and mortality amongst Caucasian, oriental Asian and South Asian CKD patients. Nephrol. Dial. Transplant. 25, 3663–3672 (2010).
Viswanathan, V. & Mirshad, R. The burden of diabetic nephropathy in India: need for prevention. Diabet. Nephrop. 3, 25–28 (2023).
Makkar, B. M. et al. RSSDI clinical practice recommendations for the management of type 2 diabetes mellitus 2022. Int. J. Diabetes Dev. Ctries. 42, 1–143 (2022).
Kidney Disease: Improving Global Outcomes (KDIGO) Diabetes Work Group. KDIGO 2022 clinical practice guideline for diabetes management in chronic kidney disease. Kidney Int. 102, S1–S127 (2022).
de Boer, I. H. et al. Diabetes management in chronic kidney disease: a consensus report by the American Diabetes Association (ADA) and kidney disease: improving global outcomes (KDIGO). Diabetes Care 45, 3075–3090 (2022).
Australian Bureau of Statistics. Aboriginal and Torres Strait Islander people: Census. https://www.abs.gov.au/statistics/people/aboriginal-and-torres-strait-islander-peoples/aboriginal-and-torres-strait-islander-people-census/2021 Accessed 16 January 2023 (2022).
Hare, M. J. L. et al. Prevalence and incidence of diabetes among Aboriginal people in remote communities of the Northern Territory, Australia: a retrospective, longitudinal data-linkage study. BMJ Open. 12, e059716 (2022).
Maple-Brown, L. J. & Hampton, D. Indigenous cultures in countries with similar colonisation histories share the challenge of intergenerational diabetes. Lancet Glob. Health 8, e619–e620 (2020).
Russell, D. J. et al. Patterns of resident health workforce turnover and retention in remote communities of the Northern Territory of Australia, 2013–2015. Hum. Resour. Health 15, 52 (2017).
Tuttle, K. R. et al. Moving from evidence to implementation of breakthrough therapies for diabetic kidney disease. Clin. J. Am. Soc. Nephrol. 17, 1092–1103 (2022).
Nicholas, S. B. et al. Prescription of guideline-directed medical therapies in patients with diabetes and chronic kidney disease from the CURE-CKD registry, 2019–2020. Diabetes Obes. Metab. 25, 2970–2979 (2023).
Jowett, M., Brunal, M.P., Flores, G. & Cylus, J. Spending targets for health: no magic number. World Health Organization. https://iris.who.int/handle/10665/250048 (2016).
Abubakar, I. et al. The Lancet Nigeria commission: investing in health and the future of the nation. Lancet 399, 1155–1200 (2022).
Bwanga, O. Barriers to continuing professional development (CPD) in radiography: a review of literature from Africa. Health Prof. Educ. 6, 472–480 (2020).
Maple-Brown, L. J., Graham, S., McKee, J. & Wicklow, B. Walking the path together: incorporating Indigenous knowledge in diabetes research. Lancet Diab. Endocrinol. 8, 559–560 (2020).
Walker, A. F. et al. Interventions to address global inequity in diabetes: international progress. Lancet 402, 250–264 (2023).
Acknowledgements
L.J.M.-B.’s work was supported by an NHMRC Investigator grant (#1194698). The Diabetes across the Lifecourse: Northern Australian Partnership would not be possible without invaluable contributions from members of the Aboriginal and Torres Strait Islander Advisory Group, Steering Committee, Management Group, and partners including government, non-government and Aboriginal community-controlled health organizations. K.R.T.’s work is supported by NIH research grants R01MD014712, U2CDK114886, UL1TR002319, U54DK083912, U01DK100846, OT2HL161847, and UM1AI109568 and CDC contract 75D301-21-P-12254.
Author information
Authors and Affiliations
Contributions
Ricardo Correa-Rotter is Professor of Medicine and Nephrology and National Researcher at the National Institute of Medical Sciences and Nutrition Salvador Zubirán (INCMNSZ), Mexico, and the National University of Mexico (UNAM). He is a member of the Academy of Medicine of Mexico, Past Secretary General of the International Society of Nephrology (ISN) and Past-President of the Latin American Society of Nephrology and Hypertension (SLANH). He serves on the editorial board of several nephrology journals and has contributed to 282 peer-reviewed articles and 65 book chapters.
Louise J. Maple-Brown is Deputy Director Research at Menzies School of Health Research, and Senior Endocrinologist at the Royal Darwin Hospital (Northern Territory, Australia). Louise has been a clinician-researcher in remote Australia for over 20 years. She established and has led the Diabetes across the Lifecourse: Northern Australian Partnership (which includes several large projects funded by Australia’s National Health and Medical Research Council) for the past 12 years.
Rakesh Sahay is Professor of Endocrinology at Osmania Medical College in Hyderabad, India. He is actively involved in research in the fields of diabetes, thyroid disorders and metabolic bone diseases. He is Past President of the Endocrine Society of India, President Elect of the Research Society for the Study of Diabetes in India, Section Editor of Tropical Endocrinology for Endotext and Associate Editor of the International Journal of Diabetes in Developing Countries.
Katherine R. Tuttle is the Executive Director for Research at Providence Inland Northwest Health and Professor of Medicine at the University of Washington, USA. She is internationally recognized for her contributions to science as well as to the care of patients with DKD. Her innovative work has produced >320 publications.
Ifeoma I. Ulasi is a nephrologist, teacher, researcher and author. She is Professor of Medicine at the College of Medicine, University of Nigeria, and is affiliated with two teaching hospitals. She is an international adviser of the Royal College of Physicians, London, a Member of the WHO Taskforce on Organ Donation and Transplantation and Past President of the Nephrology Association of Nigeria. She is also a member of various International Society of Nephrology (ISN) Committees, including the Executive Committee of the ISN (2021 to April 2023) and Deputy Chair of the ISN Advocacy Working Group (2023–2025), a member of the KDIGO CKD Guidelines Review Team (2022–2023) and a past Africa and Middle East representative of the Transplantation Society (2014–2018).
Corresponding authors
Ethics declarations
Competing interests
R.C.R. reports consultancy for Astra Zeneca, Boehringer Ingelheim, Bayer, Chinook and Dimerix. He has received research funding from Astra Zeneca, Novo Nordisk, Baxter, Roche and GSK and speaker honoraria from Amgen, Astra Zeneca, Boehringer Ingelheim, Janssen, Sanofi and Bayer. He is a member of the steering committees of World Kidney Day (2023–2026), the DAPA CKD trial (Astra Zeneca), the FINE-REAL trial (Bayer) and the national leader of the ASCEND study (GSK) and the FLOW study (Novo Nordisk). L.J.M.-B. declares no competing interests. R.S. has received lecture fees from USV India Ltd, Novo Nordisk, Lupin, Torrent Pharma and Dr. Reddy’s Laboratories. K.R.T. reports consultancy for Eli Lilly, Boehringer Ingelheim and AstraZeneca; consultancy and grants from Bayer; consultancy and speaker fees for Novo Nordisk; and grants from Travere outside the submitted work. I.I.U. has received lecture fees from Astra Zeneca, Boehringer Ingelheim and Sonofi. She is also a Principal Investigator for the Astra Zeneca CaReMe Real-world Registry for patients with kidney disease.
Additional information
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Correa-Rotter, R., Maple-Brown, L.J., Sahay, R. et al. New and emerging therapies for diabetic kidney disease. Nat Rev Nephrol 20, 156–160 (2024). https://doi.org/10.1038/s41581-023-00782-1
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41581-023-00782-1
